Providing a diverse range of perspectives from bullish to bearish, 13 analysts have published ratings on Intellia Therapeutics (NASDAQ:NTLA) in the last three months. The table below offers a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback